Investment Thesis
ALX Oncology is a pre-revenue biotech company with severe cash burn of $84.1M operating cash outflow and only $16.4M in cash reserves, creating acute runway risk. The company is unprofitable with negative operating margins and deteriorating cash position relative to burn rate, with no clear path to revenue generation in the near term.
Strengths
- Adequate current ratio of 2.07x indicates short-term liquidity sufficient for near-term operations
- Moderate debt burden with Debt/Equity of 0.39x suggests manageable leverage relative to equity base
- Recent insider activity with 14 Form 4 filings suggests ongoing executive engagement
Risks
- Zero revenue with $104M operating loss indicates failed or stalled drug development programs
- Critical cash runway concern: $16.4M cash against $84.1M annual burn rate represents less than 2.5 months of operations
- Severe profitability metrics with ROE of -391.4% and ROA of -172.2% demonstrate value destruction
- Negative $84.4M free cash flow with no offsetting revenue generation creates imminent solvency risk
- Operating cash outflow increasing relative to prior period suggests accelerating cash depletion without progress toward commercialization
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Clinical trial progress updates and regulatory milestones for pipeline assets
- Any revenue generation or partnership announcements from drug candidates
- Quarterly operating cash flow trend and burn trajectory
- Equity financing activities and dilution risk from future capital raises
Financial Metrics
Revenue
0.0
Net Income
-101.7M
EPS (Diluted)
$-1.90
Free Cash Flow
-84.4M
Total Assets
59.0M
Cash
16.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-391.4%
ROA
-172.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.07x
Quick Ratio
2.07x
Debt/Equity
0.39x
Debt/Assets
56.0%
Interest Coverage
-64.93x
Long-term Debt
10.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T18:07:16.530781 |
Data as of: 2025-12-31 |
Powered by Claude AI